CN102784237A - Pharmaceutical composition for preventing or treating diabetic complications - Google Patents
Pharmaceutical composition for preventing or treating diabetic complications Download PDFInfo
- Publication number
- CN102784237A CN102784237A CN2011101274927A CN201110127492A CN102784237A CN 102784237 A CN102784237 A CN 102784237A CN 2011101274927 A CN2011101274927 A CN 2011101274927A CN 201110127492 A CN201110127492 A CN 201110127492A CN 102784237 A CN102784237 A CN 102784237A
- Authority
- CN
- China
- Prior art keywords
- radix
- pharmaceutical composition
- diabetic
- ligustri lucidi
- rhizoma rhei
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a pharmaceutical composition for preventing or treating diabetic complications, which relates to six traditional Chinese medicines, and has definite and obvious curative effect on treating diabetic nephropathy and diabetic retinopathy.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to the pharmaceutical composition of a kind of prevention or treatment diabetic complication.
Background technology
Diabetes are common frdquently encountered diseases of serious harm human health, are the third-largest diseases that is only second to cancer and cardiovascular disease.The caused carbohydrate metabolism disturbance of diabetes causes microangiopathies, causes a series of diabetic complications then, comprises retinopathy, the sick foot of diabetic nephropathy and diabetes etc.The mechanism of diabetic microvascular complication is still not exclusively clear and definite; Think that at present non-enzymatic glycosylation dead end product forms, activation, the response to oxidative stress of APC Protein kinase C (PKC) signal path; Wherein PKC can impel VEGF (VEGF) to express; Thereby promote new vessels to form, increase vascular permeability; Wherein PKC-β mainly expresses in tissues such as retina, kidney, heart, brain and islets of langerhans; Be considered to and closely-related a kind of main hypotype [the Turtle KR of diabetic microvascular complication; Bakris GL, Toto RD, et al.The effect ofruboxistaurin on nephropathy in type 2 diabetes.Diabetes Care; 2005,28 (11): 2686-2690].
Wherein diabetic nephropathy (diabetic nephropathy, DN), (diabetic retinopathy DR) is the common and severe complications of diabetes to diabetic renal papillary necrosis.The diabetic nephropathy sickness rate be 16.8-23.48% [Han Xiaoliang, Chi Zhisheng etc. are to the research of non-insulin-dependent diabetes mellitus nephropathy, Chinese Journal of Nephrology, 1989; (5): 134 with Liu Wenqin etc., diabetic nephropathy 58 routine clinical analysiss, Chinese Journal of Nephrology, 1986; (2): 304].In a single day nephropathy takes place and becomes in diabetic, the persistence urine protein occurs, and then the state of an illness develops gradually, is to carry out sexual development until renal failure, and the mortality rate of diabetic nephropathy is 17 times of non-diabetic nephropathy.Diabetic retinopathy is the unusual a series of retinopathy that causes of retina circulation that causes owing to the diabetics carbohydrate metabolism disturbance.The automatic regulatory function mistake of basement membrane thickened, pericyte's forfeiture, blood capillary at the early stage capillary endothelial cell of pathological changes is compensatory, inner skin cell function infringement subsequently, and blood constituent oozes out, and blood capillary is inaccessible.Because retinal ischemia widely causes that retinal edema and new vessels form, concurrent vitreous hemorrhage, lead many complication such as holder property detachment of retina; Cause visual deterioration even blind [international ophthalmology magazine, in January, 2011, the 11st volume; The 1st phase, 103-105].Diabetic renal papillary necrosis can be up to 75%～80% after generally after the incidence rate of diabetics morbidity after 5 years is 25%, 10 year, increasing to 60%, 15 year.Therefore, the control of DR in treating diabetes, receive much concern always [Heilungkiang medical science, 2010, the 34th the volume, the 9th phase, 671-673].
CN1347714A discloses a kind of treatment diabetic nephropathy drugs compositions, is made up of the Radix Astragali, Fructus Ligustri Lucidi, Hirudo, Radix Et Rhizoma Rhei, Radix Pseudostellariae, Fructus Lycii.The applicant is known behind the big quantity research carrying out again on the basis of original prescription; Through wherein crude drug is carried out prescription again; Obtained to treat the pharmaceutical composition of diabetic complication, pharmaceutical composition of the present invention especially aspect treatment diabetic nephropathy and diabetic renal papillary necrosis determined curative effect obvious.
Summary of the invention
One of the object of the invention is to provide the pharmaceutical composition of a kind of prevention or treatment diabetic complication, and wherein active component is made up of following raw materials by weight percent medicine: the Radix Astragali 32～40%, Radix Pseudostellariae 10～15%, Fructus Ligustri Lucidi 16～20%, Fructus Lycii 12～18%, Hirudo 11～13%, Radix Et Rhizoma Rhei 5～8%; Be preferably the Radix Astragali 36.14%, Radix Pseudostellariae 12.05%, Fructus Ligustri Lucidi 18.07%, Fructus Lycii 14.46%, Hirudo 12.05%, Radix Et Rhizoma Rhei 7.23%.
Above-mentioned described diabetic complication is preferably diabetic nephropathy or diabetic renal papillary necrosis; Said diabetic renal papillary necrosis is early diabetic retinopathy more preferably.
Aforementioned pharmaceutical compositions can be processed powder, tablet, capsule, pill, oral liquid, granule.
The present invention also provides the method for preparing of aforementioned pharmaceutical compositions, and concrete steps are following:
1. the Radix Astragali is removed impurity, and size is separately cleaned, and runs through, and is cut into the 2-4mm sheet, 60-80 ℃ of dry for standby;
2. Radix Pseudostellariae is removed impurity, and wash quickly is clean, is cut into the 2-4mm sheet, 60-80 ℃ of dry for standby;
3. Fructus Ligustri Lucidi is removed impurity and stalk leaf, clean, and 60-80 ℃ of drying, the time spent smashs to pieces;
4. Fructus Lycii is removed impurity, chooses carpopodium, and clean and tidy back is subsequent use;
5. Hirudo is cleaned cutting, 60-70 ℃ of dry for standby;
6. Radix Et Rhizoma Rhei is removed impurity, cleans, and runs through, and cuts straight sheet, and thickness is 2-4mm, 60-80 ℃ of oven dry, and sieve goes chip subsequent use;
Radix Et Rhizoma Rhei after the said method process of preparing Chinese medicine is pulverized, crossed 100 mesh sieves, get fine powder and carry out radiation sterilization, 2KGY/ hour, exposure time was subsequent use after 3 hours; The Fructus Ligustri Lucidi that the said method of learning from else's experience was concocted add 6 times measure 75% ethanol, reflux, extract, 2-4 time each 1 hour, reclaims ethanol with alcohol extraction; The medicinal residues of Fructus Ligustri Lucidi and the Radix Astragali, Radix Pseudostellariae, Fructus Lycii, the Hirudo of concocting through said method add the water of 6 times of amounts of water, decoct 2-4 time, and each 2 hours, filtration; Merge the water extract, remove to abandon medicinal residues, the concentrated solution that fried liquid and Fructus Ligustri Lucidi reclaim behind the ethanol merges; Under-0.015-0.030MPa, concentrating under reduced pressure, temperature is 80 ℃; When being concentrated into the extractum relative density and being 1.05-1.15, be dried cream powder, promptly get with aforementioned subsequent use Radix Et Rhizoma Rhei mixing again 70 ℃ of following spray dryinges.
Pharmaceutical composition of the present invention compared with prior art, its advantage is:
The complication that pharmaceutical composition of the present invention can effectively be treated or diabetes-alleviating causes particularly has tangible curative effect to diabetic nephropathy and diabetic renal papillary necrosis, determined curative effect, and onset time is short.
Description of drawings
1, medicine pastille serum extract of the present invention to the influence of the sugared inductive Rat Mesangial PKC-β I protein kinase of height (with high sugar group ratio:
*P＜0.05,
*P＜0.01)
2, the about thing pastille of the present invention serum extract to the influence of the sugared inductive Rat Mesangial PKC-β II protein kinase of height (with high sugar group relatively,
*P＜0.05,
*P＜0.01)
3, medicine pastille serum extract of the present invention to the influence of the sugared inductive HBZY-1 emiocytosis VEGF of height (with high sugar group relatively,
*P＜0.05,
*P＜0.01)
4, medicine pastille serum extract of the present invention to the influence of the sugared inductive HBZY-1 emiocytosis TGF-β 1 of height (with high sugar group relatively,
*P＜0.05,
*P＜0.01)
The comparative example
The comparative example 1
Press the preparation of CN1347714A embodiment 1 method
The comparative example 2
Press the preparation of CN1347714A embodiment 2 methods
The comparative example 3
Press the preparation of CN1347714A embodiment 3 methods
The specific embodiment
Embodiment 1
Radix Astragali 540g, Radix Pseudostellariae 180g, Fructus Ligustri Lucidi 270g,
Fructus Lycii 216g, Hirudo 180g, Radix Et Rhizoma Rhei 108g
Said medicine is at first carried out the process of preparing Chinese medicine of Chinese crude drug:
1) Radix Astragali is removed impurity, and size is separately cleaned, and runs through, and is cut into the 2-4mm sheet, 60-80 ℃ of dry for standby;
2) Radix Pseudostellariae is removed impurity, and wash quickly is clean, is cut into the 2-4mm sheet, 60-80 ℃ of dry for standby;
3) Fructus Ligustri Lucidi is removed impurity and stalk leaf, clean, and 60-80 ℃ of drying, the time spent smashs to pieces;
4) Fructus Lycii is removed impurity, chooses carpopodium, and clean and tidy back is subsequent use;
5) Hirudo is cleaned cutting, 60-70 ℃ of dry for standby;
6) Radix Et Rhizoma Rhei is removed impurity, cleans, and runs through, and cuts straight sheet, and thickness is 2-4mm, 60-80 ℃ of oven dry, and sieve goes chip subsequent use;
Radix Et Rhizoma Rhei after the said method process of preparing Chinese medicine is pulverized, crossed 100 mesh sieves, get fine powder and carry out radiation sterilization, 2KGY/ hour, exposure time was subsequent use after 3 hours; The Fructus Ligustri Lucidi that the said method of learning from else's experience was concocted add 6 times measure 75% ethanol, reflux, extract, 2-4 time each 1 hour, reclaims ethanol with alcohol extraction; The medicinal residues of Fructus Ligustri Lucidi and the Radix Astragali, Radix Pseudostellariae, Fructus Lycii, the Hirudo of concocting through said method add the water of 6 times of amounts of water, decoct 2-4 time, and each 2 hours, filtration; Merge the water extract, remove to abandon medicinal residues, the concentrated solution that fried liquid and Fructus Ligustri Lucidi reclaim behind the ethanol merges; Under-0.015-0.030MPa, concentrating under reduced pressure, temperature is 80 ℃; When being concentrated into the extractum relative density and being 1.05-1.15, be dried cream powder, get pharmaceutical composition with aforementioned subsequent use Radix Et Rhizoma Rhei mixing again 70 ℃ of following spray dryinges.
Embodiment 2
Get the crude drug of following weight percentage:
The Radix Astragali 32%, Radix Pseudostellariae 15%, Fructus Ligustri Lucidi 20%,
Fructus Lycii 12%, Hirudo 13%, Radix Et Rhizoma Rhei 8%
It concocts basic identical with embodiment 1 with method for preparing.
Embodiment 3
Get the crude drug of following weight percentage:
The Radix Astragali 40%, Radix Pseudostellariae 10%, Fructus Ligustri Lucidi 16%,
Fructus Lycii 18%, Hirudo 11%, Radix Et Rhizoma Rhei 5%
It concocts basic identical with embodiment 1 with method for preparing.
Embodiment 4: the preparation of powder
Get embodiment 1 and make pharmaceutical composition, cross 100 mesh sieves, bag seal, the 2g/ bag is the powder finished product.
Embodiment 5: capsular preparation
Get embodiment 1 and make pharmaceutical composition, process granule, drying adds pregelatinized Starch, Pulvis Talci is an amount of, is mixed, and incapsulates, and processes 1000.
Embodiment 6: the preparation of pill
Get embodiment 2 and make pharmaceutical composition, drying is 1 hour under 60 ℃, pulverizes, and crosses 60 mesh sieves, uses pure water pill, per 20 the heavy 1g of the watered pill, and coating, polishing, 60 ℃ of dryings are the pill finished product.
Embodiment 7: the preparation of tablet
Get embodiment 3 and make pharmaceutical composition, add supplementary product starch 10%, mixing is processed granule, and drying is 1 hour under 60 ℃, tabletting, and sheet is heavy: the 0.5g/ sheet, the bag film-coat is the tablet finished product.
Embodiment 8 medicines of the present invention are to the influence of the sugared inductive HBZY-1 cell PKC-beta kinase phosphorylation of height
1. experimental technique:
To be in exponential phase HBZY-1 cell inoculation in the T75 culture bottle; Inoculum density about 80%; After cultivating 16-20h, serum starvation 24h, give rat with medicine of the present invention (by 1 preparation of embodiment method) filling stomach respectively after; Separate pastille serum and adopt the SPE method and water-soluble legal system is equipped with pastille serum extract (final concentration is respectively 1%, 2% and 4%), positive controls (2 μ mol/LGF109203X (inhibitors of protein kinase C)), hatch 2h for 37 ℃; After the washing; Add high concentration glucose again; Final concentration is 30mmol/L, and collecting cell behind the cultivation 4h adds RIAP lysate (50mmol/L Tris-HCl (pH7.4), 150mmol/L NaCl, 1%NP-40,1mmol/L EDTA, 0.25%sodium deoxycholate, 1mmol/L Na
3VO
4, 1mmol/L NaF, 1mmol/LPMSF and 2 μ g/mL Leupeptin) ice bath 30min, frozen-thawed four times, centrifugal, obtain cell lysate, adopt the method for western blot to measure the expression of HBZY-1 cell PKC-β I, PKC-β II protein kinase.Method is following: the BCA method is measured the total protein of cell amount, adjusts each sample to same concentrations, and SDS-PAGE separates and is transferred on the pvdf membrane, behind 37 ℃ of sealings of 5% defatted milk powder 2h, adds one anti-(1: 200) respectively, hatches 2h for 37 ℃; Add corresponding two anti-IgG-HRP (1: 3000) again and hatch 1h for 37 ℃.ECL luminescence reagent box is used the gel imaging system chemiluminescence detection and is carried out gray analysis with Image lab system, is confidential reference items with β-actin.
2, result:
Concrete outcome is seen Fig. 1 and 2, and the result shows that high concentration glucose stimulates can cause that Rat Mesangial PKC-β I and PKC-β II tyrosine phosphorylation increase; And after medicine pastille serum extract of the present invention pretreatment, PKC-β I and PKC-β II protein kinase level obviously reduce, and have the significant concentration dependency.
Embodiment 9 medicine pastille serum extracts of the present invention are induced Rat Mesangial secretion of VEGF, TGF-β 1 to high sugar influence
1, experimental technique
Adopt well-grown HBZY-1 cell to experimentize.Be divided into following 8 groups: concentration group (final concentration 2%), pastille bilirubin at high serum group (4%) in normal control group (5.6mmol/L D-glucose), high sugar group (30mmol/LD-glucose), positive controls (2 μ mol/L GF109203X (inhibitors of protein kinase C)), medicine of the present invention (pressing 1 preparation of embodiment method) pastille serum low concentration group (final concentration 1%), the pastille serum, every group of two multiple hole.Handle 24h, 48h collecting cell culture supernatant respectively at administration, utilize VEGF in the ELISA kit detection cell culture supernatant, TGF-β 1 content, detection method is referring to the test kit description.
2, experimental result:
1, ELISA testing result (Fig. 3) shows: compare with normal control, after high concentration glucose (30mmol/L) stimulated different time, VEGF content obviously increased in the culture supernatant; And after the medicine pastille serum of the present invention pretreatment of variable concentrations, VEGF content has reduction in various degree in the HBZY-1 cells and supernatant that high sugar stimulates.And positive control GF109203X also can obviously suppress high sugar stimulation HBZY-1 emiocytosis VEGF increase.The result shows that medicine of the present invention can effectively suppress high sugared inductive Rat Mesangial secretion of VEGF and increase.
2, ELISA testing result (Fig. 4) shows: compare with normal control, after high concentration glucose (30mmol/L) stimulated different time, TGF-β 1 content obviously increased in the culture supernatant; After the medicine pastille serum extract of the present invention pretreatment of variable concentrations, TGF-β 1 content has reduction in various degree in the HBZY-1 cells and supernatant that high sugar stimulates.And positive control GF109203X also can obviously suppress high sugar stimulation HBZY-1 emiocytosis TGF-β 1.The result shows that medicine of the present invention can obviously suppress high sugared inductive Rat Mesangial secretion TGF-β 1 and increase.
Embodiment 10 pharmaceutical compositions of the present invention are estimated the rat pharmacodynamics of diabetic nephropathy model
1. experimental technique
(Sichuan Academy of Medical Sciences institute of lab animals provides to choose healthy male SD rat; The quality certification number: SCXK (river) 2008-24); The SPF level; Body weight 180～220g, each organizes the dosage single tail vein injection STZ (2% sodium citrate solution of PH4.2) of rat by 55mg/kg, and rats in normal control group is then given equivalent 2% sodium citrate solution tail vein injection.Tail vein blood is surveyed blood glucose value behind the 48h, fasting glucose for three days on end >=16.7mmol/L, urine amount >=crude urine amount is confirmed as the diabetes model rat.4 week back treatment groups irritate respectively stomach give captopril (21mg/kgd) and medicine A (by comparative example's 1 preparation) (2.0g/kgd), medicine B (by comparative example's 2 preparations) (2.0g/kgd), medicine C (by comparative example's 3 preparations) (2.0g/kgd), medicine D (press embodiment 2 preparations) (2.0g/kgd), medicine E (pressing embodiment 1 prepares) (2.0g/kgd), medicine F (pressing embodiment 3 prepares) (2.0g/kgd); Blank group, model control group are then irritated stomach equal-volume distilled water every day, and each organizes continuous 8 weeks of administration.The 2nd, 4,8 all metabolic cages are collected record 24h urine amount behind drug treatment, microtrabeculae measurement in chromatography glycolated hemoglobin, and fasting glucose content detects the 24h urine protein content with the Coomassie brilliant blue method; In the 8th all last administrations after 1 hour; Femoral artery puncture is got blood; Separation of serum is measured serum triglycerides (TG), T-CHOL (TC) content, serum creatinine (Scr), blood urea nitrogen (BUN), creatinine clearance rate (Ccr); Take by weighing simultaneously and respectively organize rat kidney and body weight, calculate kidney heavy (KWT) and kidney/body weight (KWT/BWT).
2. result
2.1 influence to diabetic nephropathy model rat blood sugar, glycolated hemoglobin
The influence of table 1 pair rat model fasting glucose, glycolated hemoglobin
Compare ###P＜0.001 with the blank group; Compare with model control group,
*P＜0.05,
*P＜0.01,
* *P＜0.001
Can know by table 1 result; Each drug group of the present invention all can obviously reduce the content of rat model blood glucose, glycolated hemoglobin; 2 weeks of administration, 4 weeks, 8 all just abilities are the content of blood sugar lowering, glycolated hemoglobin obviously, the content of remarkable blood sugar lowering of medicine E ability of the present invention and glycolated hemoglobin.
2.2 influence to diabetic nephropathy model rat 24h urine amount, urine albumen amount
The influence
of table 2 pair rat model 24h urine amount, urine albumen amount
Compare ###P＜0.001 with the blank group; Compare with model control group,
*P＜0.05,
*P＜0.01,
* *P＜0.001;
Can be known that by table 2 result each drug group of the present invention all can reduce the content of rat model 24h urine amount and urine protein in various degree, medicine E wherein of the present invention effect is comparatively obvious, and obvious effect (P＜0.05～0.001) is all arranged in 2 weeks of administration, 4 weeks, 8 weeks.
2.3 influence to diabetic nephropathy model rat blood serum BUN, Scr, Ccr
The influence
of table 3 couple rat model serum BUN, Scr, Ccr
Compare ###P＜0.001 with the blank group; Compare with model control group,
*P＜0.05,
*P＜0.01,
* *P＜0.001;
Can know that by table 3 each drug group of the present invention all can reduce rat model BUN, Scr content in various degree, reduce Ccr and then alleviate glomerule ultra filtration load, the protection renal function, medicine E wherein of the present invention effect is (P＜0.01～0.001) comparatively obviously.
2.4 influence to diabetic nephropathy model rat KWT, KWT/BWT
The influence of table 4 couple rat model KWT, KWT/BWT
Compare ###P＜0.001 with the blank group; Compare with model control group,
*P＜0.05,
*P＜0.01;
* *P＜0.001
Can be known that by table 4 each drug group of the present invention all can reduce rat model KWT, KWT/BWT in various degree, the early stage kidney injury of rat model is had the significant protection effect, medicine E wherein of the present invention effect is (P＜0.001) comparatively obviously.
2.5 influence to diabetic nephropathy model rat TG, TC
The influence of table 5 pair rat model serum TG, TC content
Compare ###P＜0.001 with the blank group; Compare with model control group,
*P＜0.05,
*P＜0.01
Can be known that by table 5 each drug group of the present invention all can reduce rat model serum TG, TC content in various degree, the rat model blood fat is raise has obvious reduction effect effect, and medicine E wherein of the present invention effect is (P＜0.01) comparatively obviously.
Embodiment 9, pharmaceutical composition of the present invention are to the hemodynamic pharmacodynamics evaluation of rat retina central artery
1, test method
Get 300 of normal male Wistar rats, with 50mg/kg dosage through the disposable injection streptozotocin of tail vein (0.1mmol/L, the sodium citrate buffer of pH 4.4 is made into 1%STZ).Injecting docked after 72 hours gets blood; Measure fasting glucose; All fasting glucose >=16.7mmol/L person is diabetes rat model; The continuation normal feedstuff was fed 3 months, measured the rat retina hemodynamic parameter, as if the subclinical phase that then can confirm as animal pattern entering sugar net disease unusually according to " the clinical research guideline that the new Chinese medicine treatment of diabetic retinopathy becomes " that hemodynamic parameter occurs.
Get in the preventive experiment injection STZ after 72 hours blood glucose rise to 70 of the diabetes rat models of 16.7mmol/L; Be divided into 5 groups at random with fasting glucose: model control group (equal-volume normal saline), positive controls (0.5g calcium dobesilate/kg body weight), medicine D (pressing embodiment 2 preparations) (0.5g medicated powder/kg body weight), medicine E (pressing embodiment 1 preparation) (0.5g medicated powder/kg body weight), medicine F (pressing embodiment 3 preparations) (0.5g medicated powder/kg body weight); Every group 14, other gets with 10 of batch normal rats and is normal control group (equal-volume normal saline).Each organizes 24 weeks of successive administration, and normal control group and model control group give isopyknic normal saline.Adopt 30mg/kg pentobarbital sodium ip anesthetized rat after the last administration; Hemodynamics with Sequoia512 type CDFI appearance every rat retina of right eye central artery of mensuration (CRA) comprises peak systolic VPV (Max), flow velocity diastasis (Min), TAV (TAMx).
Get 70 of subclinical sugar futures net disease model rats in the curative test; Be divided into 5 groups at random with hemodynamic index: model control group (equal-volume normal saline), positive controls (0.5g calcium dobesilate/kg body weight), pharmaceutical composition of the present invention 2 groups of (0.5g medicated powder/kg body weight), pharmaceutical composition of the present invention 5 groups of (0.5g medicated powder/kg body weight), 6 groups of pharmaceutical compositions of the present invention (0.5g medicated powder/kg body weight); Every group 14, other gets with 10 of batch normal rats and is normal control group (equal-volume normal saline).Each organizes 12 weeks of successive administration, and normal control group and model control group give isopyknic normal saline.Adopt 30mg/kg pentobarbital sodium ip anesthetized rat after the last administration; Hemodynamics with Sequoia512 type CDFI appearance every rat retina of right eye central artery of mensuration (CRA) comprises peak systolic VPV (Max), flow velocity diastasis (Min), TAV (TAMx).
2, result of the test
Table 6 pharmaceutical composition is to the hemodynamic influence of diabetic retinopathy rat CRA (prevention group)
Annotate: model group and normal control group are relatively
△ △ △P＜0.001, administration group and model group are relatively
*P＜0.01
* *P＜0.001
Table 6 is the result show; Model group rat CRA blood flow velocity obviously reduces; Max, Min, the equal highly significant of TAMx are lower than the normal control group same period, and reflection retinal blood infusate flow and blood supply wretched insufficiency compare with model group; Each dose groups rat CRA blood flow velocity of pharmaceutical composition of the present invention obviously increases, and each dose groups all has highly significant property meaning.The result shows that pharmaceutical composition of the present invention can significantly improve diabetic retinal tissue in rat central artery blood perfusion and blood supply insufficiency, and diabetic retinopathy is had significant preventive effect, and wherein pharmaceutical composition E is the most remarkable.
Table 7 pharmaceutical composition is to the hemodynamic influence of sick rat CRA (treatment group)
of diabetic sugar net
Annotate: model group and normal control group are relatively
△ △ △P＜0.001, administration group and model group are relatively
*P＜0.05
* *P＜0.001
Table 7 is the result show; Model group rat CRA blood flow velocity obviously reduces; Max, Min, the equal highly significant of TAMx are lower than the normal control group same period, and reflection retinal blood infusate flow and blood supply wretched insufficiency compare with model group; Each dose groups rat CRA blood flow velocity of pharmaceutical composition of the present invention obviously increases, and each dose groups all has highly significant property meaning.The result shows that pharmaceutical composition of the present invention can significantly improve diabetic retinal tissue in rat central artery blood perfusion and blood supply insufficiency, and diabetic retinopathy is had significant therapeutic effect, and wherein pharmaceutical composition E is the most remarkable.
Claims (7)
1. the pharmaceutical composition of prevention or treatment diabetic complication is characterized in that active component is made up of following raw materials by weight percent medicine: the Radix Astragali 32～40%, Radix Pseudostellariae 10～15%, Fructus Ligustri Lucidi 16～20%, Fructus Lycii 12～18%, Hirudo 11～13%, Radix Et Rhizoma Rhei 5～8%.
2. pharmaceutical composition according to claim 1 is characterized in that said active component is made up of following raw materials by weight percent medicine: the Radix Astragali 36.14%, Radix Pseudostellariae 12.05%, Fructus Ligustri Lucidi 18.07%, Fructus Lycii 14.46%, Hirudo 12.05%, Radix Et Rhizoma Rhei 7.23%.
3. pharmaceutical composition according to claim 1 and 2 is characterized in that described diabetic complication is a diabetic nephropathy.
4. pharmaceutical composition according to claim 1 and 2 is characterized in that described diabetic complication is a diabetic renal papillary necrosis.
5. pharmaceutical composition according to claim 1 and 2 is characterized in that said pharmaceutical composition can process powder, tablet, capsule, pill, oral liquid, granule.
6. pharmaceutical composition according to claim 4 is characterized in that it being that described diabetic renal papillary necrosis is an early diabetic retinopathy.
7. claim 1 or 2 described preparation of pharmaceutical compositions methods is characterized in that:
1) Radix Astragali is removed impurity, and size is separately cleaned, and runs through, and is cut into the 2-4mm sheet, 60-80 ℃ of dry for standby;
2) Radix Pseudostellariae is removed impurity, and wash quickly is clean, is cut into the 2-4mm sheet, 60-80 ℃ of dry for standby;
3) Fructus Ligustri Lucidi is removed impurity and stalk leaf, clean, and 60-80 ℃ of drying, the time spent smashs to pieces;
4) Fructus Lycii is removed impurity, chooses carpopodium, and clean and tidy back is subsequent use;
5) Hirudo is cleaned cutting, 60-70 ℃ of dry for standby;
6) Radix Et Rhizoma Rhei is removed impurity, cleans, and runs through, and cuts straight sheet, and thickness is 2-4mm, 60-80 ℃ of oven dry, and sieve goes chip subsequent use;
Radix Et Rhizoma Rhei after the said method process of preparing Chinese medicine is pulverized, crossed 100 mesh sieves, get fine powder and carry out radiation sterilization, 2KGY/ hour, exposure time was subsequent use after 3 hours; The Fructus Ligustri Lucidi that the said method of learning from else's experience was concocted add 6 times measure 75% ethanol, reflux, extract, 2-4 time each 1 hour, reclaims ethanol with alcohol extraction; The medicinal residues of Fructus Ligustri Lucidi and the Radix Astragali, Radix Pseudostellariae, Fructus Lycii, the Hirudo of concocting through said method add the water of 6 times of amounts of water, decoct 2-4 time, and each 2 hours, filtration; Merge the water extract, remove to abandon medicinal residues, the concentrated solution that fried liquid and Fructus Ligustri Lucidi reclaim behind the ethanol merges; Under-0.015-0.030MPa, concentrating under reduced pressure, temperature is 80 ℃; When being concentrated into the extractum relative density and being 1.05-1.15, be dried cream powder, promptly get with aforementioned subsequent use Radix Et Rhizoma Rhei mixing again 70 ℃ of following spray dryinges.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110127492.7A CN102784237B (en) | 2011-05-17 | 2011-05-17 | Pharmaceutical composition for preventing or treating diabetic complications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110127492.7A CN102784237B (en) | 2011-05-17 | 2011-05-17 | Pharmaceutical composition for preventing or treating diabetic complications |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410538033.1A Division CN104352645A (en) | 2011-05-17 | 2011-05-17 | Pharmaceutical composition for preventing or treating diabetic complications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102784237A true CN102784237A (en) | 2012-11-21 |
| CN102784237B CN102784237B (en) | 2015-11-25 |
Family
ID=47149956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110127492.7A Active CN102784237B (en) | 2011-05-17 | 2011-05-17 | Pharmaceutical composition for preventing or treating diabetic complications |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102784237B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104713953A (en) * | 2013-12-13 | 2015-06-17 | 成都康弘制药有限公司 | Fingerprint detection method of medicines |
| CN107281315A (en) * | 2016-04-11 | 2017-10-24 | 成都康弘制药有限公司 | Traditional Chinese medicine pellet and preparation method thereof |
| CN112190646A (en) * | 2020-11-19 | 2021-01-08 | 首都医科大学附属北京中医医院 | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352645A (en) * | 2011-05-17 | 2015-02-18 | 成都康弘制药有限公司 | Pharmaceutical composition for preventing or treating diabetic complications |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1347714A (en) * | 2001-05-21 | 2002-05-08 | 成都康弘制药有限公司 | Chinese herb. medicine composition for treating diabetes and nephropathy and its preparing method |
-
2011
- 2011-05-17 CN CN201110127492.7A patent/CN102784237B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1347714A (en) * | 2001-05-21 | 2002-05-08 | 成都康弘制药有限公司 | Chinese herb. medicine composition for treating diabetes and nephropathy and its preparing method |
Non-Patent Citations (3)
| Title |
|---|
| 侯方: "糖尿病视网膜病变的中医临床治疗进展", 《北京中医药大学学报（中医临床版）》 * |
| 李健等: "渴络欣含药血清萃取物抑制高糖诱导的大鼠系膜细胞增殖及ERK1/ 2 磷酸化的研究", 《四川大学学报（医学版）》 * |
| 李蓉等: "近10年糖尿病视网膜病变中医药研究概况", 《新疆中医药》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104713953A (en) * | 2013-12-13 | 2015-06-17 | 成都康弘制药有限公司 | Fingerprint detection method of medicines |
| CN104713953B (en) * | 2013-12-13 | 2017-06-30 | 成都康弘制药有限公司 | A kind of assay method of medicine finger-print |
| CN107281315A (en) * | 2016-04-11 | 2017-10-24 | 成都康弘制药有限公司 | Traditional Chinese medicine pellet and preparation method thereof |
| CN112190646A (en) * | 2020-11-19 | 2021-01-08 | 首都医科大学附属北京中医医院 | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102784237B (en) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101590101A (en) | A kind of prescription and preparation technology who treats type and complication thereof | |
| CN107080010A (en) | It is a kind of can anti-trioxypurine cyclocarya paliurus tea and preparation method thereof | |
| CN102784237B (en) | Pharmaceutical composition for preventing or treating diabetic complications | |
| CN102319256B (en) | Application of porphyra polysaccharide in preparing treatment medicament or prevention health-care product of kidney diseases | |
| CN104815166B (en) | A kind of Chinese medicine composition for treating diabetes and its preparation and application | |
| CN104971190A (en) | Application of dioscorea cirrhosa in preparation of medicines for preventing or treating diabetes and complications of diabetes | |
| CN101647951B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN101843814A (en) | Chinese medicinal compound preparation for treating gout and hyperuricemia and preparation method thereof | |
| CN103550281A (en) | Medicine composition for preventing and treating diabetes and diabetes complications and preparation thereof | |
| CN106421581A (en) | Biological traditional Chinese medicine for oral administration for treating diabetes and preparation method thereof | |
| CN104740054B (en) | A kind of pharmaceutical composition for preventing and treating myocardial ischemia and its production and use | |
| CN101991757B (en) | Chinese medicinal composition for reinforcing kidney and supporting yang and preparation method thereof | |
| CN105343506A (en) | Method for preparing composition for treating type-2 diabetes | |
| CN101537079B (en) | Pharmaceutical composition or health-care product for improving sleeping and delaying senility and preparation method thereof | |
| CN104815140A (en) | Composition for preventing or/and treating diabetes and preparation method of composition | |
| CN101053598B (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN104352645A (en) | Pharmaceutical composition for preventing or treating diabetic complications | |
| CN1718191A (en) | Total secondary ginseng glucoside oral disintegration tablets prepn. method and application thereof | |
| CN108186799A (en) | Ground bone slender acanthopanax dissipates and preparation method | |
| CN101791351B (en) | Glipizide-containing traditional Chinese and western medicine composition | |
| CN101791350B (en) | Glibenclamide-containing traditional Chinese and western medicine composition | |
| CN100496522C (en) | Medicinal composition containing propolis, preparation method and use thereof | |
| CN107029124A (en) | It is a kind of to be used to treat Chinese medicine composition of essential hypertension and preparation method thereof | |
| CN105194676A (en) | Medicine composition for treating hyperlipemia and preparation method of medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121121 Assignee: Sichuan Jishengtang Pharmaceutical Co., Ltd. Assignor: Kanghong Pharmaceutical Co., Ltd., Chengdu Contract record no.: 2017510000030 Denomination of invention: Medicinal composition for preventing and treating diabetic complications Granted publication date: 20151125 License type: Common License Record date: 20171018 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220525 Address after: No. 309, Tianfu East Road, Pengzhou Industrial Development Zone, Chengdu, Sichuan 611930 Patentee after: Sichuan Jishengtang Pharmaceutical Co.,Ltd. Address before: 610036 No. 36 Shu West Road, Chengdu, Sichuan, Jinniu District Patentee before: Chengdu Kanghong Pharmaceutical Co.,Ltd. |